Impact on follow-up strategies in patients with primary sclerosing cholangitisKings Coll Hosp London, England.
Kings Coll Hosp London, England; Pomeranian Med Univ, Poland.
Univ Alberta, Canada.
Univ Alberta, Canada.
Med Univ Warsaw, Poland.
Med Univ Warsaw, Poland.
Univ Med Ctr Hamburg Eppendorf, Germany.
Univ Med Ctr Hamburg Eppendorf, Germany.
Univ Padua, Italy; Univ Padua, Italy.
Univ Padua, Italy.
Sahlgrens Univ Hosp, Sweden.
Hannover Med Sch, Germany; European Reference Network Hepatol Dis, Germany.
Hannover Med Sch, Germany; European Reference Network Hepatol Dis, Germany.
Univ Bonn, Germany.
Univ Bonn, Germany.
Gen Univ Hosp Larissa, Greece.
Gen Univ Hosp Larissa, Greece.
Univ Miami, FL USA.
Ghent Univ Hosp, Belgium; Univ Ghent, Belgium.
Univ Ghent, Belgium; European Reference Network Hepatol Dis, Belgium.
Oslo Univ Hosp, Norway; Univ Bergen, Norway; Haraldsplass Deaconess Hosp, Norway.
Friedrich Alexander Univ Erlangen Nurnberg, Germany; Univ Hosp Erlangen, Germany; Univ Hosp Zurich, Switzerland.
Univ Duisburg, Germany.
Univ Hosp, Sweden.
Lund Univ, Sweden; Skåne Univ Hosp, Sweden.
Akershus Univ Hosp, Norway.
Karolinska Univ Hosp, Sweden; European Reference Network Hepatol Dis, Stockholm, Sweden.
Karolinska Univ Hosp, Sweden.
Örebro Univ, Sweden.
Univ Coll Hosp NHS Fdn Trust, England.
Oslo Univ Hosp, Norway.
Umeå Univ, Sweden.
Univ Svizzera Italiana, Switzerland.
Univ Politecn Marche, Italy.
Helsinki Univ Hosp, Finland.
Univ Helsinki, Finland.
Karolinska Univ Hosp, Sweden.
Karolinska Inst, Sweden.
Univ Helsinki, Finland; Helsinki Univ Hosp, Finland.
Hannover Med Sch, Germany; European Reference Network Hepatol Dis, Hannover, Germany; Univ Duisburg, Univ Hosp Essen, Germany.
Show others and affiliations
2023 (English)In: Liver international (Print), ISSN 1478-3223, E-ISSN 1478-3231, Vol. 43, no 1, p. 127-138Article in journal (Refereed) Published
Abstract [en]
Background & Aims: Evidence for the benefit of scheduled imaging for early detection of hepatobiliary malignancies in primary sclerosing cholangitis (PSC) is limited. We aimed to compare different follow-up strategies in PSC with the hypothesis that regular imaging improves survival.
Methods: We collected retrospective data from 2975 PSC patients from 27 centres. Patients were followed from the start of scheduled imaging or in case of clinical follow-up from 1 January 2000, until death or last clinical follow-up alive. The primary endpoint was all-cause mortality.
Results: A broad variety of different follow-up strategies were reported. All except one centre used regular imaging, ultrasound (US) and/or magnetic resonance imaging (MRI). Two centres used scheduled endoscopic retrograde cholangiopancreatography (ERCP) in addition to imaging for surveillance purposes. The overall HR (CI95%) for death, adjusted for sex, age and start year of follow-up, was 0.61 (0.47-0.80) for scheduled imaging with and without ERCP; 0.64 (0.48-0.86) for US/MRI and 0.53 (0.37-0.75) for follow-up strategies including scheduled ERCP. The lower risk of death remained for scheduled imaging with and without ERCP after adjustment for cholangiocarcinoma (CCA) or high-grade dysplasia as a time-dependent covariate, HR 0.57 (0.44-0.75). Hepatobiliary malignancy was diagnosed in 175 (5.9%) of the patients at 7.9 years of follow-up. Asymptomatic patients (25%) with CCA had better survival if scheduled imaging had been performed.
Conclusions: Follow-up strategies vary considerably across centres. Scheduled imaging was associated with improved survival. Multiple factors may contribute to this result including early tumour detection and increased endoscopic treatment of asymptomatic benign biliary strictures.
Place, publisher, year, edition, pages
Chichester, United Kingdom: Wiley-Blackwell, 2023. Vol. 43, no 1, p. 127-138
Keywords [en]
cholangiocarcinoma; ERCP; follow-up strategy; MRI; primary sclerosing cholangitis; surveillance
National Category
Other Clinical Medicine
Identifiers
URN: urn:nbn:se:liu:diva-185381DOI: 10.1111/liv.15286ISI: 000796360700001PubMedID: 35535655Scopus ID: 2-s2.0-85131595748OAI: oai:DiVA.org:liu-185381DiVA, id: diva2:1662654
Note
Funding Agencies: Swedish Cancer Society; Stockholm County Council; Cancer Research Funds of Radiumhemmet
2022-06-012022-06-012023-04-05Bibliographically approved